(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031


Substitute for form 1449A-B/PTO Complete if Known TRADEMA pplication Number 09/247,886 INFORMATION DISCLOSURE Filing Date February 10, 1999 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen Group Art Unit 1633 Examiner Name S. Chen (use as many sheets as necessary) **Attorney Docket Number** 02-030210US **Date Submitted** March 25, 2002

	0:4-	U.S. Patent Docu		Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	(if known)		Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
	1	5,252,714		Harris et al.	10-12-1993	
	2	5,348,867		Georgiou et al.	09-20-1994	
	3	5,512,463		Georgiou et al.	09-20-1994	
	4	5,514,588		Varadaraj	05-07-1996	
	5	5,571,698		Ladner et al.	11-05-1996	_
	6	5,691,170		Gritz et al.	11-25-1997	2
	7	5,763,239		Short et al.	06-09-1998	, C
	8	5,789,228		Lam et al.	08-04-1998	TOR CONTROL OF THE PROPERTY OF
	9	5,814,473		Warren et al.	09-29-1998	12 3 K
	10	5,862,514		Kauffman et al	10-20-1998	CP, Co, O
	11	5,866,344		Georgiou	02-02-1999	0/3
	12	5,876,997		Kretz	03-02-1999	Ely,
	13	5,882,883		Egel-Mitani et al.	03-16-1999	
	14	5,925,749		Mathur, et al.	07-20-1999	
	15	5,939,300		Robertson, et al.	08-17-1999	
	16	5,942,430		Robertson, et al.	08-24-1999	
	17	5,948,666		Callen, et al.	09-07-1999	
	18	5,958,751		Murphy, et al.	09-28-1999	
	19	5,962,258		Mathur, et al.	10-05-1999	
	20	5,962,283		Warren et al.	10-05-1999	
	21/	5,985,285		Titball et al.	11-16-1999	
-/	22	5,985,646		Murphy, et al.	11-16-1999	
	23	6,043,030		Beach et al.	03-28-2000	

Examiner Shin-Lin Chin Signature	Date Considered	8-29-02
----------------------------------	--------------------	---------



		19A-B/PTO		1.5	/		Complete # 1/= :			
Substitute f	or form 144	19A-B/PTO	/		nnlination Number		complete if Know	vn		
INICODIA	ATION D		TRADEMA	\$\f	pplication Number		09/247,886	1000		
STATEMENT BY APPLICANT					iling Date		February 10,			
					irst Named Invento	<u>r </u>	Juha Punnor	<u>ien</u>		
					roup Art Unit xaminer Name		1633 S. Chen			
(use as many sheets as necessary)				_	ttorney Docket Nur	nhor	02-030210US			
•					ate Submitted	IIDEI	March 25, 20			
				_	ate Submitted		Mai Ci 25, 20	02		
24	6,054,	312		l a	cocca et al.		04-25-2000			7
25	6,087,				avari et al.		07-11-2000		-/	$\overline{}$
26	6,153,				nold et al.		11-28-2000		/	
27	6,156,			+	hatz et al.		12-05-2000			
	6,159,			Vir						
28	6,159,						12-12-2000			
29	6,165,			+	orchert et al.		12-12-2000			
30	6,165,			-	orchert et al.		12-26-2000			
31			ļ	+	Stemmer		12-26-2000		À —	
32	6,168,			+	ort		01-02-2001	2 40		
33	6,171,	<u> </u>		Sh	ort		01-09-2001	100,0	مِساءُ و	
34	6,174,			Short et al. Arnold et al.			12-12-2000 12-12-2000 12-26-2000 01-02-2001 01-09-2001 01-16-2001 01-23-2001 01-30-2001		-20 N	
35	6,177,								b	
36	6,180,			St	Stemmer et al.		01-30-2001	Š	730	
37	6,194,			Má	arkvardsen et al.		02-27-2001			
38	6,238,			Sh	ort et al.		05-29-2001			
39	6,251,	674		То	bin et al.		06-26-2001			
40	6,261,	561		Sto	ewart, Jr. et al.		07-17-2001			
41	6,287,	861		Sto	emmer et al.		09-11-2001			i
		/								
										4
			FOF	EIG	N PATENT DOCUM	/ENT	rs			4
wami Cita		Foreign Patent D		024-	Name of Patentas a		Date of Publication	Pages, Colum		Т
xami Cité ner No. nitials	Office	Number	Kind (if kn		Name of Patentee of Applicant of Cited Docur		of Cited Document MM-DD-YYYY	Where Relevan or Relevant Figu		
42	EP	0 125 228	A1		President and Fellows of Harvar College	ď	06-15-1988			
		J								
				,			q			
xaminer	1	in-Li	1	As A		Date	e	8-38	<u> </u>	
	5 N	11-11	VI U	YU	()		-	8-2/-0	V	
Signature	, ,					Con	sidered			



Substitute for form 1449A-B/PT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Λ	<u> </u>	omplete if Known	
	Application Number	09/247,886	
	Filing Date	February 10, 1999	
ı	First Named Inventor	Juha Punnonen	
	Group Art Unit	1633	
	Examiner Name	S. Chen	
	Attorney Docket Number	02-030210US	
	Date Submitted	March 25, 2002	

	43	EP	0 725081	A1	Kyowa Hakko Kogyo Co., Ltd.	08-07-1996		/
	44	EP	0876509	B1	Maxygen, Inc.	09-19-2001		
	45	EP	0911396	A2	Stemmer	04-28-1999		
	46	EP	0911396	A3	Stemmer et al.	05-06-1999		
	47	EP	0934999	A1	Stemmer et al.	08-11-1999		
	48	wo	90/14443		Huse	11-29-1990		
	49	wo	91/07979		Center for Innovative Technology	06-13-1991	THE THE	
	50	wo	92/03461		Ixsys, Inc.	03-05-1992	C. 10 CA	
	51	wo	92/06204		Ixsys, Inc.	04-16-1992	8000	
	52	wo	92/11272		Ixsys, Inc	07-09-1992	To 3	ス
	53	wo	93/06214		The United States of America	04-01-1993	Copy of the same o	
	54	wo	93/10214		Georgiou	05-27-1993	8,	
	55	wo	94/06421		The University of Tennessee Research	03-31-1994		
	56	wo	94/23738	A1	Medisorb Technologies International L.P.	10-27-1994		
	57	wo	94/26787	A1	The Boead of Trustees of the Leland Stanford Junior University	11-24-1994		
	58	wo	95/16027	A1	Borrebaeck	06-15-1995		
<u></u>	59	wo	96/11279	A1	US Department of Health and Human Services	04-18-1996		

Considered Signature



TRADEMAP Complete if Known Substitute for form 1449A-B/PTO 09/247,886 Application Number INFORMATION DISCLOSURE Filing Date February 10, 1999 STATEMENT BY APPLICANT Juha Punnonen First Named Inventor Group Art Unit 1633 S. Chen **Examiner Name** (use as many sheets as necessary) Attorney Docket Number 02-030210US March 25, 2002 **Date Submitted**

	60	wo	96/13250	A1	Amgem, Inc.	05-09-1996		
-	61	wo	96/37624		MG-PMC, L.L.C.	11-28-1996		
	62	wo	97/04077		Recombinant Biocatalysis, Inc.	02-06-1997		
	63	WO	97/07128	A1	Duke University	02-27-1997		
	64	wo	97/07205		Okkels	02-27-1997		
	65	WO	97/11605	A1	University of Pittsburg of the Commonwealth System of Higher Education	04-03-1997	FO 200 200	
	66	wo	97/25410		Borchert et al	07-17-1997	CA	
	67	wo	97/32987	A1	University of Toronto	09-12-1997	1/2 1/3 1/1/2	
	68	wo	97/44361		Lam et al.	11-27-1997	Why so s	
	69	wo	97/48416	•	Mathur et al.	12-24-1997	CP 103	
	70	wo	97/48717		Short et al.	12-24-1997	0/20	
	71	wo	97/48794		Murphy et al.	12-24-1997	60.	
	72	wo	98/00526		Robertson et al.	01-08-1998		
	73	wo	98/01581		Short	01-15-1998		
	74	WO	98/05764		Novo Nordisk	02-12-1998		
	75	wo	98/05765		Novo Nordisk	02-12-1998		
	76	wo	9 8/24799		Bylina	06-11-1998		
	77	wø	98/28416		Bjornvad et al.	07-02-1998		
	78	wo	98/36080		Affholter et al.	08-20-1998		
	79	wo	98/41622		Borchert et al.	09-24-1998		
	80	wo	98/41623		Borchert et al.	09-24-1998		
	81	wo	98/41653		Vind et al.	09-24-1998		

Examiner Signature	Shin-Lin	Chen	Date Considered	8-29-02
-----------------------	----------	------	--------------------	---------

MAR 2 9 2007 8 3014

Substitute for form 1449A-B/PTO	C	omplete if Known
Substitute for form 1449A-B/PTO	Application Number	09/247,886
INFORMATION DISCLOSURE	Filing Date	February 10, 1999
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen
	Group Art Unit	1633
	Examiner Name	S. Chen
(use as many sheets as necessary)	Attorney Docket Number	02-030210US
	Date Submitted	March 25, 2002

						-		
4re	82	wo	98/42727		SRI International		10-01-1998	
1	83	wo	98/42832		Arnold et al.		10-01-1998	
	84	wo	98/45444		The Regents of the University of California	ne	10-15-1998	
	85	wo	98/48034		Neiboer et al.		10-29-1998	
	86	wo	98/49286		Board of Regents The University of Texas System		11-05-1998	AR OF TOP
	87	wo	98/58085		Short et al.		12-23-1998	78
	88	wo	99/07837		Callen		02-18-1999	
	89	wo	99/08539		Kretz		02-25-1999	300
	90	wo	99/10472		Short		03-04-1999	N/22 308
	91	wo	99/10539		Short		03-04-1999	7/6/2
	92	wo	99/19506		lxsys, Inc.		04-22-1999	2900
	93	wo	99/19518		Short		04-22-1999	
	94	wo	99/21979		Apt et al.	ï	05-06-1999	
	95	wo	99/23107		Stemmer et al.		05-14-1999	
	96	wo	99/23236		Diversa Corp. et a	al.	05-14-1999	
	97	wo	99/29902		Arnold et al.		06-17-1999	
	98	wo	99/41366		The Board of Trustees of the Leland Stanford Junior University		08-19-1999	
	99	wo	99/41368		Maxygen, Inc.		08-19-1999	
	100	wo	99/41369		Maxygen, Inc.		08-19-1999	
	101	wo	99/41383		Maxygen, Inc.		08-19-1999	
42	102	wo	99/41402		Maxygen, Inc.		08-19-1999	
Exami Signat		5)	un-Lin	Cher	1	Date Con	e esidered	Jester



Substitute for form 1449A-B/PT
INFORMATION DISCLOSURE RADEMARY
STATEMENT BY APPLICANT

i Co	omplete if Known
Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number

(use as many sheets as necessary)

						1000
5W	113	wo	01/00234	Maxygen, Inc	01-04-2001	Ep, 193
	112	wo	00/58517	Short et al.	10-05-2000	Con 3
	111	wo	00/53744	Short et al.	09-14-2000	CCL PR
	110	wo	00/46344	Diversa Corrporation	08-10-2000	
	109	WO.	00/42561	Crameri et al.	07-20-2000	S _A
	108	wo	00/42560	Selifonov et al.	07-20-2000	
	107	wo	00/18778	Phylos, Inc.	04-06-2000	
	106	wo	00/16984	Polard Corporation	03-30-2000	
	105	wo	99/65927	Maxygen, Inc,	12-23-1999	
i	104	WO	99/57128	Stemmer et al.	11-11-1999	
4h	103	wo	99/45154	Short et al.	09-10-1999	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exami ner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
44	114	Affholter et al. (1998) "Directed evolution of proteins and pathways by DNA shuffling." Book of Adstracts, 216th ACS National Meeting, Boston, August 23-27, BIOT-042	
-	115	Agren et al. (1997) "Genetically Engineered Nontoxic Vaccine Adjuvant That Combines B Cell Targeting with Immunomodulation by Cholera Toxin A1 Subunit." J. Immunol 158:3936	
	116	Ahmed (1995) J Bacteriology 177(14):3904-3910	
	117	Ahn et al. (1996) "Human cytomegalovirus inhibits antigen presentation by a sequential multistep process." <i>Proc. Natl. Acad, Sci USA</i> 93:10990	
	118	Aizaki et al. (1998) "Full-Length Complementary DNA of Hepatitus C Virus Genome From an Infectious Blood Sample." <i>Hepatology 27:621-627 (1998)</i>	
	119	Aldovini & Young (1991) "Humoral and cell-mediated immune response to live recombinant BCG-HIV vaccines." <i>Nature</i> 351:479-482	
SW	120	Ambriovic, A. et al. (1997) "Efficacy of Replication-Defective Adenovirus-Vectored Vaccines: Protection Following Intramuscular Injection Is Linked to Promoter Efficiency in Muscle Representative Cells" Virology 238:, 327-335	

Examiner Signature	shin-Lin	chen	Date Considered	Jestor
-----------------------	----------	------	--------------------	--------



Substitute for form 1449A-B/PTO	Co	omplete if Known
TRADEMAR	Application Number Filing Date	09/247,886
INFORMATION DISCLOSURE	Filing Date	February 10, 1999
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen
	Group Art Unit	1633
	Examiner Name	S. Chen
(use as many sheets as necessary)	Attorney Docket Number	02-030210US
	Date Submitted	March 25, 2002

GN -	121	Appel and Harris (1998) "Antiboby titers in domestic ferret fills and kits to canine distemper virus vaccines." <i>JAVMA</i> 193:332-333
ĺ	122	Atkins et al. (1996) "Manipulation of the Semliki Forest Virus Genome and Its Potential for Vaccine Construction." <i>Mol Biotechnol</i> 5:33-38
	123	Axon (1998) "Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives." <i>Gut</i> 43(1):S70-3
	124	Baba et al., "Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC," The J. of Biolog. Chem. 272 (23): 14893-14898 (1997).
	125	Bass et al. (1990) "Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties." <i>Proteins: Structures, Function and Genetice</i> 8:309-314
	126	Beck et al., "DNA Sequence Analysis of 66 kb of the Human MHC Class II Region Encoding a Cluster of Genes for Antigen Processing," J. Mol. Biol. 228:433-441 (1992)
	127	Behrens et al. (1996) "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus." <i>EMBO J.</i> 15:12-22
	128	Benham et al. (1997) "Proteasome activity limits the assembly f HMC class 1 molecules after IFN-gamma stimulation." <i>J. Immol</i> 159(2):5896-5904
	129	Berkhout et al. (1999) "Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type I Vaccine Strains." <i>J. Virology</i> 73(2):1138-1145
	130	Bernard et al. (1994) "Transcriptional Control and Cell Type Specificity of HPV Gene Expression." Arch Dermatol 130:210
	131	Bhatnagar et al. (1982) "Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant." <i>Proc Nat'l Acad Sci USA</i> 79:4400-4404
	132	Bielefeldt-Ohmann, H. et al., "Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system," J. Gen. Virol. 78:2723-2733 (1997)
	133	Blachere et al., "Heat Shock Protein-Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphyocyte Response and Tumor Immunity," J. Exp. Med. 186:1315-22 (1997)
	134	Blanchard et al. (1998) "Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins" J. Gen. Virol 79:1159-1167
	135	Blaser (1998) "Helicobacter pylori and gastric disease." BMJ 316:1507-1510
	136	Bloom et al. (1993) Characterization of Chimeric Full-Length Molecular Clones of Aleutian Mink Disease Parvovirus (ADV) " J. Virol 67(10):5976-5988
	137	Bolhuis (1995) <i>J. Biological Chamistry</i> 270(3):26092-26098
	138	Botstein and Shortle, "Strategies and Applications of in Vitro Mutagenesis," Science 229:1193-1201 (1985)
	139	Boursnell et al. (1997) "A Genetically Inactivated Herpes Simplex Virus Type 2 (Hsv-2) Vaccine Provides Effective Protection against Primary & Recurrent HSV-2 Disease." <i>J. Infect. Dis</i> 175:16-25
	140	Bray et al. (1989) "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengus Virus Encepha;it is." <i>J. Virol</i> 63:2853-2856
1	141	Bridgen and Elliot (1996) "Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNA's." <i>Proc. Nat'l Acad. Sci USA</i> 93:15400-15404
N	142	Brocke et al. (1996) "Treatment of experimental encephalomyelitis with a peptide analogue of myelin
,		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through Examiner Signature

March 25, 2002



TRADEMAN Complete if Known Substitute for form 1449A-B/PTO Application Number 09/247,886 INFORMATION DISCLOSURE Filing Date February 10, 1999 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen Group Art Unit 1633 **Examiner Name** S. Chen (use as many sheets as necessary) Attorney Docket Number 02-030210US

Date Submitted

		basic protein." Nature 379:343-346
		Brubaker (1991) "The V Antigen of Yersiniae: An Overview." Current Investigations of the Microbiology
4rd	143	of Yersinae 12:127-133
1	144	Burger et al. (1995) Proc. of thr Amer Assoc. for Cancer Research 36:522 Abst #3108
	145	Burke et al. (1999) "Formulation, Stability and Delivery of Live Attenuated Vaccines for Human Use." Crit. Rev. Ther Drig. Carrier Syst 16:1-83
	146	Burton (1995) "Phage Display." Immunotechnology 1(2):87-94
	147	Carroll and Moss (1997) "Host range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus" Virology 238:198-211
	148	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors," Nucl. Acids Res. 13:4431-4443 (1985)
	149	Carter, "Improved Oligonucleotide-Directed Mutagenesis Using M13 Vectors," Methods in Enzymol. 154:382-403 (1987)
	150	Carter, "Site-directed mutagenesis," Biochem. J. 237:1-7 (1986)
	151	Casal (1999) "Use of parvovirus-like particles for vacation and induction of multiple immune response." Biotechnol Appl. Biochem 29:-141-150
	152	Cathomen et al. (1998) "A matrix-less measles virus is infectious and extensive cell fusion: consequences for propagation in the brain." <i>EMBO J.</i> 17(14):3899-3908
	153	Chang, C., et al. (1999) "Evolution of a cytokine using DNA family shuffling." Nature Biotechnology 17:793-797.
	154	Chen et al. "Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis." Science 265:1237-1240
	155	Chen et al., "Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phase peptide library," Proc. Nat'l. Acad. Sci. USA 93:1997-2001 (1996)
	156	Chin et al. (1993) "Functions and Regulation of the Human Miltidrug Resistance Gene." Adv. Cancer Res. 60:157-180
	157	Chu et al. (1995) "A Vaccina Virus-Vectored Hantaan Virus Vaccing Protects Hamsters from Challenge with Hantaan and Seoul Viruses but Not Pumala Virus." J. Virol 69:6417
	158	Clackson et al. (1994) "In vitro selection from protein and peptide libraries." <i>Trends Biotechnol</i> 12(5): 173-184
	159	Coco et al., (2001) "DNA shuffling method for generating highly recombined genes and evolved enzymes" Nature Biotechnology vol. 19 pp. 354-359
	160	Collman et al. (1992) "An Infectious Molecular Clone of an Unusual Macrophage-Tropic and Highly Cytopathic Strain of Human Immunodeficiency Virus Type 1." <i>J. Virol</i> 66(12):7517-7521
	161	Conry et al. (1996) "Selected strategies to augment polynucleotide immunization." Gene Therapy 3(1):67-74
	162	Cote et al. (1986) "Protection of Chimpanzees from Type B Hepatitis by Immunization with Woodchuck Hepatitis Virus Surface Antigen." <i>J. Virol</i> 60:895-901
4M	163	Crabtree (1998) "Eradication of chronic Helicobacter pylori infection by therapeutic vaccination." Gut 43:7-8

Examiner Signature	Shin-Lin	Chen	Date Considered	StrENTER 2000
			-	

March 25, 2002

Substitute for form 1449A-B/PTO	Co	omplete if Known
TRAN	Constitution Number	09/247,886
INFORMATION DISCLOSURE	Filing Date	February 10, 1999
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen
	Group Art Unit	1633
	Examiner Name	S. Chen
(use as many sheets as necessary)	Attorney Docket Number	02-030210US

Date Submitted

GN	164	Craiu et al., "Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide," Proc. Nat'l. Acad. Sci. USA 94:10850-10855 (1997)
1	165	Crameri & Stemmer (1993) "10(20)-fold aptamer library amplification without gel purification." Nucleic Acids Research 21(18): 4410
	166	Cresswell & Hughes, "Protein degradation: The ins and outs of of the matter," Curr. Biol. 7:R552-R555 (1997)
	167	Cwirla et al. (1990) "Peptides on Phage: A vast library of peptides for identifying ligands." <i>Proc. Nat'l Acad Sci USA</i> 87:6378-6382
	168	Davis et al (1995) "DNA-based immunization." <i>Molecular and Cell Biology of Human Gene Therapeutics</i> 5:368-387
	169	Davis et al. (1989) "In vitro Synthesis of Infectious Venezuelar Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant." <i>Virology</i> 171:189-204
	170	Davis et al. (1997) "DNA-Baised immunization against hepatitis B surface antigen (HBsAg) in Normal and HBsAg-transgenic mice." <i>Vaccine</i> 15(8) 849-822
	171	Devlin et al. (1990) "Random Peptide Libraries: A Source of Specific Protein Binding Molecules." Science 249:404-406
	172	Dieu et al. ,"Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites," J. Exp. Med. 188:373-386 (1998)
	173	DiMarco et al. (1997) "Agnostic and antagonistic variants of ciliary neurothrophic Factor (CNTF) Reveal functional differences between mambrean-bound and soluble CNTF Alpha-receptors." <i>J Biol. Chem.</i> 272(37):23069-23075
	174	Donovan et al. (1987) "Genes Encoding Spore Coat Polypeptides from Bacillus subtilis." J. Mol Biol 196:1-10
	175	Drabkin et al. (1996) "Amber Suppression in Mammalian Cells Dependent upon Expression of an Escherichia coli Aminoacyl-tRNA Synthetase Gene." <i>Mol Cell. Biol.</i> 16(3):907-913
	176	Dubols et al. (1998) "Immunization against Natural Helicobacter pylori Infection in Nonhuman Primates." <i>Infect. Immun.</i> 66:4340-4346
	177	Dunn (1996) "Phage display of proteins." <i>Curr Opin Biotechnology</i> 7(5):547-553
	178	Eghtedarzadeh and Henikoff, "Use of oligonucleotides to generate large deletions," Nucl. Acids Res. 14:5115 (1986)
	179	Engels and Ackermann (1996) "Pathogenesis of ruminant herpesvirus infections." <i>Vet Microbiol</i> 53:3-15
	180	Felici, Franco et al., "Peptide and protein display on the surface of filamentous bacteriophage," Biotechnol. Annu. Rev. 1:149-83 (1995)
	181	Fields et al., "Crystal structure of a T-cell receptor B-chain complexed with a superantigen," Nature 384:188-192 (1996)
	182	Francisco, Joseph A. et al., "Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface," Proc. Nat'l. Acad. Sci. USA 90:10444-10448 (1993)
	183	Frankel and Young (1998) "HIV-1 Fifteen Proteins and an RNA." Annu. Rev. Biochem 67:1-25
5M	184	Freeman et al., "B7-1 and B7-2 Do Not Deliver Identical Costimulatory Signals, Since B7-2 but Not B7-1

Since B7-2 but No.

Since B7-2 but No.

609. Drawling through Shin-Lin Chen Date Examiner Considered Signature

March 25, 2002



TRADEMP Complete if Known Substitute for form 1449A-B/PTO 09/247,886 **Application Number** INFORMATION DISCLOSURE Filing Date February 10, 1999 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen Group Art Unit 1633 S. Chen **Examiner Name** (use as many sheets as necessary) Attorney Docket Number 02-030210US

Date Submitted

		Preferentially Costimulates the Initial Production of IL-4," Immunity 2:523 (1995)
<i>y</i> , ,	405	Fritz et al. "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure
1/2	185	without enzymatic reactions in vitro," Nucl. Acids Res. 16:6987-6999 (1988)
'	186	Gaczynska et al.,"Proteasome Subunits X and Y alter Peptidase Activities in Opposite Ways to the
1	100	Interferon-y-induced Subunits LMP2 and LMP7*,J. Biol. Chem. 271:17275-17280 (1996)
	187	Galler et al. (1997) "The Yellow fever 17D vaccine virus: molecular basis of viral attnuation and its use
1 1	107	as an expression vector." J. Med Biol. Res. 30:157-168
	188	Galocha et al. (1997) "The Active Site of ICP47, a Herpes Simple Virus-encoded Inhibitor of the Major
	100	Histocompatibility Complex" J. Exp. Med 185:1565-1572
	189	Garnett and Grenfell (1992) "The epidemiology of varicella-zoster virus infections: the influence of
		varicella on the prevalence of herpes zoster." Epidemiol. Infect 108:513-528
	190	Geigenmuller et al. (1997) "Construction of a Genome-Length cDNA Clone for Human Astrovirus
		Serotype 1 and Synthesis of Infectious RNA Transcrips." J. Virol 71:1713-1717
	191	Goldman et al. (1999) Molecular Cloning and Expression of Major Structural Protein " J. Virol.
		73:4465-4469
	192	Gritsun et al. (1998) "Development and analysis of a tick-bone encephalitis virus infectious clone using
		a novel and rapid strategy." J Virol. Methods 76:109-120
	193	Groettrup et al. "The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S
		proteasome," Proc. Nat'l. Acad. Sci. USA 94:8970-8975 (1997)
	194	Groettrup et al., "A third interferon –γ-induced subunit exchange in the 20S proteasome," Eur. J.
1		Immunol. 26:863-869 (1997)
1	195	Groux et al.,"A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis,"
1 1		Nature 389:737 (1997)
	196	Grundstrom et al., "Oligonucleotide-directed mutagenesis by microscale 'shot-gun' gene synthesis,"
1 1		"Nucleic Acids Res. 13:3305-3316 (1985) Gualano et al. (1998) "Identification of a major determinant of mouse neurovirulence of dengue virus
	197	typw 2 using stably cloned genomic-length cDNA." <i>J. Gen. Virol.</i> 79:437-466
+ +		Guo et al. (1998) "Susceptibility to recombination rearrangements of a chimeric plum pox potyvirus
	198	genome after insertion of a foreign gene." <i>Virus Res</i> 57:183-195
+	400	Halminen et al. (1997) "Expression of MXA Protein in Blood Lymphocytes Discriminates between Viral
	199	and Bacterial Infections in Febrile Children." <i>Pediatric Research</i> 41:647-650
+	000	Han, Xiaoliang et al., "Ligand-directed retroviral targeting of human breast cancer cells," Proc. Natl.
	200	Acad. Sci USA 92:9747-9751 (1995)
	201	Hanes, Jozef and Andreas Pluckthun., "In vitro selection and evolution of functional proteins by using
	201	ribosome display," Proc. Nat'l. Acad. Sci. USA 94(10):4937-42 (1997)
1	202	Haq et al. (1995) "Oral Immunization with a Recombinant Bacterial Antigen Produced in Transgenic
	202	Plants." Science 268:714-716
7	203	Haralambiev (1967) "Immunogenicity Studies on a Inactivated IBR Vaccine Administered Into the Nasal
	203	Mucosa." Acta Vet Acad Sci Hung 26:215-217
	204	Harrington et al. (1992) "An outbreak of Respiratory Syncytial Virus in a Bone Marrow Transplant
	<u> </u>	Center." J. Infect Dis. 165:987-993
4N	/205	HCJ Ertl et al., (1996) "Genetic Immunization" Viral Immunization Vol. 9, No. 1, pp. 1-9.
7' '	200	

pp. 1-9.

Drawling through Shin-Lin Chen Date Examiner Considered Signature



Substitute for form 1449A-B/PTO	Co Application Number Filing Date	omplete if Known
The reaction	**Xpplication Number	09/247,886
INFORMATION DISCLOSURE	Filing Date	February 10, 1999
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen
	Group Art Unit	1633
	Examiner Name	S. Chen
(use as many sheets as necessary)	Attorney Docket Number	02-030210US
	Date Submitted	March 25, 2002

4N	206	He et al., "Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites," Nucl. Acids Res. 25(24):5132-4 (1997)		
1	207	He et al. (1998) "The Paramyxovirus SV5 Small Hydrobhobic (SH) Protein Is Not Essential for Virus Growth in Tissue Culture Cells." <i>Virology</i> 250:30-40		
	208	Hensel and Lubitz (1997) Vaccination by Aerosols: Modulation of Clearance Mechanism in the Lung." Behring, Inst. Mitt. 98:212-219		
	209 Hill et al., "Phage presentation," Mol Microbiol 20(4):685-92 (1996)			
	210	Hoffman and Banerjee (1997) "An Infectious Clone of Human Parainfluenza Virus Type 3." <i>J Virol.</i> 71:4272-4277		
	211	Hohol et al. (1996) "Three-year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a phase III Pivotal Trial." Ann. N.Y. Acad Sci. 778:243-250		
	212	Holzmann, H. et al., "Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes," Vaccine 10:345 (1992)		
	213	Hopkins and Yoder (1986) "Reversion to Virulence of Chicken-Passaged Infectious Bronchitis Vaccine Virus." Avain Dis. 30:221-223		
	214	Hourvitz et al. (1996) "Reactogenicity and immunogenicity of a new recombinant hepatitis B Vaccine		
	215	containing Pre S Antigens." <i>J Virol. Hepatitis</i> 3:37-42 Hristov and Karadjov (1975) <i>Vet Med Nauki</i> 13:5		
	216	Huang, Sharon K.S. et al., "Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma Patients," J. Invest. Dermatol. 111:662-7 (1998)		
	217	Hui, George S.N. et al., "Dominance of Conserved B-Cell Epitopes of the Plasmodium falciparum Merozoite Surface Protein, MSP1, in Blood-Stage Infections of Naïve Actus Monkeys," Infect. Immun. 64:1502-1509 (1996)		
	218	Hulskotte at al. (1998) "Towards an HIV-1 vaccine: lessons from studies in macaque models." Vaccine 16:904-915		
	219	Hurtado et al. (1996) "Identification of Domains in Canine Parvovirus VP2 Essential for the Accembly of Virus-Like Particles." <i>J. Virol</i> 70:5422-5429		
	220	lacono-Connors et al., Virus Res. 43:125-136 (1996)		
	221	Irvine, K.R. et al., "Cytokine Enhancement of DNA Immunization Leads to Effective Treatment of Established Pulmonary Metastases," Journal of Immunology, 156:238-245 (1996)		
	222	Jia et al. (1995) "A Novel virant of avain infectious bronchitis virus resulting from recombination among three different strains." <i>Arch Virol</i> 140:259-271		
	223	Jiang et al. (1999) "Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles." <i>Vaccine</i> 17:1005-1013		
	224	Jiang et al. , "Subtraction hybridization identified a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression," Oncogene 11:2477 (1995)		
	225	Jiang et al., "The melanoma differentiation associated gene mda-7 suppresses cancer cell growth," Proc. Nat'l. Acad. Sci. USA 93:9160 (1996)		
41	226	Jin et al. (1998) "Recombinant Human Respiratory Synctial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV." Virology 251:206-214		
Examiner Shin-Lin Men Date Considered Fig.		Shin-Lin Men Date Considered Considered whether or not citation is in conformance with MPEP 609 (Draw line through		
		*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Down line through		
citation	if not in	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Daw line through conformance and not considered. Include copy of this form with next communication to applicant.		
		Page 11 of 21		



Substitute for form 1449A-B/PTO	Application Number Filing Date	omplete if Known
TRADEN	Application Number	09/247,886
INFORMATION DISCLOSURE	Filing Date	February 10, 1999
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen
	Group Art Unit	1633
	Examiner Name	S. Chen
(use as many sheets as necessary)	Attorney Docket Number	02-030210US
	Date Submitted	March 25, 2002

314	227	Johnston, et al. (1997) "Genetic to genomic vaccination" Vol. 15, no. 8 pp 808-809
1	228	Kang et al. (1999) "Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-like Particles." Biol. Chem 380:353-364
	229	Karandikar et al.,"CTLA-4: A Negative Regulator of Autoimmune Disease," J. Exp. Med. 184:783 (1996)
	230	Keck. Et al. (1988) "In Vivo RNA-RNA Recombination of Coronavirus in Mouse Brain." <i>J. Virol.</i> 62:1810-1813
	231	Keenan et al.,"Lack of Protection following immunisation with H. pylori outer membrane vesicles highlights antigenic differences between H. felis and H. pylori," FEMS Microbiol Lett. 161:21-7 (1998)
	232	Khavari, (1997) " Therapeutic gene delivery to the skin" Molecular Medicine Today, Dec. 1997: 533538
	233	Kim et al., "In Vivo Engineering of a Cellular Immune Response by Coadministration of IL-12 Expression Vector with a DNA Immunogen," J. Immunol. 158:816 (1997)
	234	Kim, et al. (1997) "Development of a multicomponent candidate vaccine for HIV-1" Vaccine, Vol. 15 No. 8 pp 879-883.
	235	Kinney et al. (1997) "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53." <i>Virology</i> 230:300-308
	236	Kinney et al., "Recombinant Vaccinia Virus/Benezuelan Equine Encephalitis (VEE) Virus Protects Mice from Peripheral VEE Virus Challenge," J. Virol. 62:4697 (1998)
	237	Kleanthous et al., "Vaccine development against infection with Helicobacter pylori," Br. Med. Bull. 54:229-41 (1998)
	238	Klinman et al., "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon □," Proc. Nat'l. Acad. Sci. USA 93:2879 (1996)
	239	Klinman, D.M. et al., "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," Journal of Immunology, 158:3635-3639 (1997)
	240	Kobayashi et al.,"Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989)
	241	Kobyashi, Yuzuru et al., "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," Infect. Immun. 44:117 (1984)
	242	Kochel, Tadeusz et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine 15:547-552 (1997)
	243	Kodama et al., "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 343:531-535 (1990)
	244	Konishi et al.,"A Highly Attentuated Host Range-Restricted Vaccinia Virus Strain, NYVAC, Encoding the prM, E and NS1 Genes of Japanese Encephalitis Virus Prevents JEV Viremia in Swine," Virology 190:454 (1992)
	245	Koopman et al., "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," Curr. Opin. Immunol. 9:80-88 (1997)
	246	Kramer and Fritz, "Oligonucleotide-Directed Construction of Mutations via Gapped Duplex DNA," Methods in Enzymol. 154:350-367 (1987)
SU	247	Kramer et al. "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," Nucl. Acids Res. 16:7207 (1988)

Examiner Signature	Shin-Lin chen	Date Considered	Sol Bic
	*EXAMINER: Initial if reference considered, whether or r	not citation is in conformanc	with MPER 609. Draw line through
citation if not in	conformance and not considered. Include copy of this form w	ith next communication to a	• • • • • • • • • • • • • • • • • • •

MAR 2 9 2002

Substitute for form 1449A-B/PTO Complete if Known 09/247,886 Application Number TRADEMAR INFORMATION DISCLOSURE Filing Date February 10, 1999 First Named Inventor Juha Punnonen STATEMENT BY APPLICANT Group Art Unit 1633 S. Chen **Examiner Name** (use as many sheets as necessary) **Attorney Docket Number** 02-030210US March 25, 2002 **Date Submitted**

4	248	Kramer et al., "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl- Directed DNA Mismatch-Repair System of E. coli," Cell 38:879-887 (1984)
}	249	Kramer et al., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1984)
	250	Krieg et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546 (1995)
the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 609 (1992) Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amin		Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992)
		Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement," EMBO J. 11:3237-3244 (1992)
	253	Kuchroo et al. , "B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707 (1995)
	254	Kunkel et al. , "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Methods in Enzymol. 154:367-382 (1985)
	255	Kunkel , "The efficiency of oligonucleotide directed mutagenesis" Nucleic acids & Molecular Biology 2: 124-135 (1988)
	256	Kunkel, "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Proc. Nat'l. Acad. Sci. USA 82:488-492 (1985)
	257	Lagranderie et al. (1993) "BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route." <i>Tubercle and Lung Disease</i> 74:38-46
	258	Lai et al. (1991) "Infectious RNA transcribed from stabily cloned full-length cDNA of dengue type 4 Virus." <i>Proc. Nat'l Acad. Sci. USA</i> 88:5139-5143
	259	Lanar et al. (1996) "Attanuated Vaccinia Virus-Circumsporoziote Protein Recombinants Confer Protection against Rodent Malaria." <i>Infect Immun</i> 64:1666-1671
	260	Lanciotti et al. (1994) "Molecular evolution and epidemology of dengue-3 viruses." <i>J Gen Virol</i> . 75:65-75
	261	Larsen et al., Long Term acceptance of Skin and Cardiac Allografts After Blocking CD40 and CD28 Pathways,"Nature 381: 434 (1996).
	262	Laud et al., Human Immunol. 50:91-102 (1996)
	263	Leary et al.,"Active Immunization with Recombinent V Antigen from Yersinia Pestis Protects Mice against Plague," Infect. Immun. 3:2854 (1995)
and comparasion to other infectious CVB cDNAs." Virus Res 50:255-235		Lee et al., (1997) "Generation of an Infectious cDNA of a highly cardiovirulent coxsakievirus B3(CVB3m) and comparasion to other infectious CVB cDNAs." <i>Virus Res</i> 50:255-235
	265	Lee et al., "Optimal Induction of Hepatitis C Virus Envelope-Specific Immunity by Bicistronic Plasmid DNA Inoculation with the Granulocyte-Macrophage Colony-Stimulating Facter Gene," J. Virol 72:8430-6 (1998)
	266	Lehrer et al. (1998) "Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis." FEMS Immunol. Med. Mircobiol. 21:71-77
	267	Leung et al. (1989) Technique 1(1):11-15
GU	268	Li et al. (1997) "Expression of the Human Papillomavirus Type 11 L1 Capsid Protein in Escherichia coli" J. Virol 71(4):2988-2995

MPEP 609. Draw line through Shin-Lin Chen Date Examiner Considered Signature

02-030210US March 25, 2002

Approved for use through 10/31/99. OMB 0651-0031 TRADEMA Complete if Known Substitute for form 1449A-B/PTO 09/247,886 **Application Number** INFORMATION DISCLOSURE Filing Date February 10, 1999 First Named Inventor Juha Punnonen STATEMENT BY APPLICANT Group Art Unit 1633 S. Chen **Examiner Name**

Attorney Docket Number

Date Submitted

(use as many sheets as necessary)

4W	269	Li et al.,"Cloning and functional characterization of a subunit of the transporter associated with antigen processing," Proc. Natl. Acad. Sci USA 94: 8708-8713 (1997).
i	270	Liao et al. (1990) Gene 107-111
	271	Liao et al., STRL22 is a Receptor for the CC Chemokine MIP-3α," Biochem. and Biophys. Comms. 236: 212-217 (1997).r
	272	Liblau et al. "Th1 and Th2 CD4+ cells in the pathogenesis of organ-specific autoimmune diseases," Immunol. Today 16:34-38 (1995)
	273	Liem et al. (1994) Nucleic Acids Res 22(9):1613-1619
	274	Lieschke et al.,"Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," Nature Biotech. 15:35 (1997)
	275	Limbach and Paoletti (1996) "Non-replicating expression vectors: applications in vaccine development and gene therapy." <i>Epidemol. Infect.</i> 116:241-256
	276	Lowe et al. (1997) "Human Papillamavirus Typw 2 (HPV-11) Nutralizing Antibobies in the Serum and Genitial Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like particles Expressed in Yeast." J. Invect Dis 176:1141-1145
	277	Lowman, Henry B. and Jame A. Wells, "Affinity Maturation of Human Growth Hormone by Monovalent Phage Display," J. Mol. biol. 234:564-578 (1993)
	278	Lowman, Henry B. and James A. Wells, "Monovalent Phage Display: A Method for Selecting Variant Proteins from Random Libraries," Methods: A Companion to Methods Enz. 3(3):205-216 (1991)
	279	Lu, Zhijian et al., "Expression of Thioredoxin Random Peptide Libraries on the Escherichia coli Cell Surface as Functional Fusions to Flagellin: A System Designed for Exploring Protein-Protein Interactions," Bio/Technology 13:366-372 (1995)
	280	Luytjes et al. (1989) "Amplification, Expressionand Packaging of a Foreign Gene by Influenza Virus." Cell 59:1107-1113
	281	Mandl et al. (1997) "Infectious cDNA clones of tick-borne encephalitis virus European subtype protopic strain Neudoerfl and high virulence strain Hypr." <i>J. Gen. Virol</i> 78:1049-1057
	282	Marchetti, Marta et al., "Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant." Vaccine 16:33-7 (1998)
	283	Marusina et al.,"Allelic Variation in the Mouse Tap-1 and Tap-2 Transporter Genes," J. Immunol. 158:5251-5256 (1997)
	284	Mattheakis, Larry C. et al., "An in vitro polysome display system for identifying ligands from very large peptide libraries," Proc. Nat'l. Acad. Sci. USA 91(19):9022-6 (1994)
	285	McAtee, C. Patrick et al., "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter pylori by "Proteome" Technologies," Helicobacter 3:163-9 (1998)
	286	McAtee, C. Patrick et al., "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter pylori by Two-Dimensional Gel Electrophoresis, Sequence Analysis, and Serum Profiling," Clin. Diagn. Lab. Immunol. 5:537-42 (1998)
	287	McCutcheon et al. "A senstive ELISPOT assay to detect low-frequency human T lymphocytes,", J. Immunol. Methods 210:149-66 (1997)
m	288	McGregor, Duncan, "Selection of Proteins and Peptides from Libraries Displayed on Filamentous

109. Draw line through Shin-Lin Chen Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609



Substitute for form 1449A-B/PT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

\$/ C	omplete if Known
Application Number	09/247,886
Filing Date	February 10, 1999
First Named Inventor	Juha Punnonen
Group Art Unit	1633
Examiner Name	S. Chen
Attorney Docket Number	02-030210US
Date Submitted	March 25, 2002

			Bacteriophage," Mol Biotechnol. 6(2):155-62 (1996)
1.1	,	000	Melen et al., "Enzymatic Characterization of Interferon-Induced Antiviral GTPases Murine Mx1 and
4n		289	Human MxA Proteins," J. Biol, Chem. 269: 2009-2015 (1994).
		290	Metz et al. (1996) "Bicistronic and Two-Gene Retroviral Vectors for Using MDR1 as a Selectable Market
			and a Therapeutic Gene." Virology 217:230-241
		291	Meulenberg et al. (1998) "An Infectious cDNA Clone Porcine Reproductive and Respiratory Syndrome
			Virus." Coronaviruses and Arteriviruses 440:199-206
		292	Meulenberg et al. (1998) "Infectious Transcrips from Cloned Genome-Length cDNA of Porcine
	_		Reproductive and Respiratory Syndrome Virus." J. Virol. 72:380-387
		293	Meyer et al. (1998) "Bovine herpesvirus type 1 glycoprotein H is essential for penetration and and propagation in cell culture." J. Gen Virol. 79:1983-1987
		294	Mittelholzer et al. (1997) "Generation of cytopathogenic RNA of classical swine fevor in persistently
		204	infected porcine cell lines." Virus Res 51:125-137
		295	Monaco , "Pathways for the processing and presentation of antigens to T cells," J. Leukocyte Biol. 57:543-57 (1995)
		296	Morita et al. (1987) "Recombinant vaccinia virus LC16m0 or LC1m8 that expresses hepatitus B surface
		200	antigen while preserving the attention of the parental virus." Vaccine 5:65-70
		297	Mosmann and Coffman, Adv. Immunol. 46:111 (1989)
1		298	Moss (1994) "Replicating and Host-Restricted Non-Replicating Vaccina Virus Vectors for Vaccine
			Development." Dev. Biol. Stand 82:55-63
		299	Mundt and Vakharia (1996) "Synthetic transcripts of double-stranded Birnavirus genome are
	4		infectious." Proc Nat'l Acad. Sci USA 93:11131-11136
- 1		300	N. Miller et al., (1995) "Targeted vectors for gene therapy," FASEB J., 9, pp. 190-199.
		301	Nakamaye and Eckstein, "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate
			groups and its application to oligonucleotide-directed mutagenesis," Nucl. Acids Res. 14:9679-9698 (1986)
		302	Nambiar et al.,"Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S Protein," Science 223:1299-1301 (1984)
	\neg	303	Nazerian et al. (1996) "Protection and synerhism by Recombinant Fowl Pox Vaccines Expressing
	\perp		Genes from Marek's Disease Virus." Avian Dis. 40:368-376
		304	Nemoto, Naoto et al., "In vitro virus: Bonding of mRNA bearing puromycin at the 3'-terminal end to the
	_		C-terminal end of its encoded protein on the ribosome in vitro," FEBS Lett. 414(2):405-8 (1997)
		305	Ness, J. et al., (1999) "DNA shuffling of subgenominc sequences of subtilisin." Nature Biotechnology 17:893-896.
	\top	306	Neurath, A.R. et al., "Monoclonal Antibodies to Hepatitis BSurface Antigen (HBsAg) with Anti-a
			Specificity Recognize A Synthetic Peptide Analogue (S135-155) with Unmodified Lysine (141)," J. Virol. Methods 9:341-346 (1984)
	\neg	307	Ni and Barrett, "Nucleotide and deduced amino acid sequence of the structural protein genes of
		307	Japanese encephalitis viruses from different geographical locations,"J. Gen. Virol. 76:401 (1995)
		Notka et al. (1999) "Constructon and Characterization of Recombinant VLPs and Semliki-Forest Virus	
	1		Live Vectors for Comparative Evaluation in the SHIV Monkey Model." <i>Biol Chem</i> 380:341-352

Examiner Signature	Shin-Lin chen	Date Considered	Andra Maria
citation if not in	*EXAMINER: Initial if reference considered, whether or not ci a conformance and not considered. Include copy of this form with no	ext communication to a	



TRANEM T Complete if Known Substitute for form 1449A-B/PTO pplication Number 09/247,886 INFORMATION DISCLOSURE Filing Date February 10, 1999 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen Group Art Unit 1633 **Examiner Name** S. Chen (use as many sheets as necessary) **Attorney Docket Number** 02-030210US Date Submitted March 25, 2002

4r	309	O'Neil, Karyn T. et al., "Phage display: protein engineering by directed evolution," Curr. Opin. Struct. Biol. 5(4):443-9 (1995)			
-	310	Oda Kobe J. Med. Sci. 22:123 (1976)			
	311	Orme (1997) "Progress in the development of new vaccines against tuberculosis." Int. J. Tuberc. Jung. Dis 1:95-100			
	312	Ortmann et al.,"A Critical Role for Tapasin in the Assembly and Function of Multimeric MHC Class 1- TAP Complexes," Science 277: 1306-1309 (1997).			
	313	Paoletti et al. (1995) "Highly Attenuated Poxvirus: HYVAC, ALVAC and TROVAC," Dev Biol Stand 84:159-163			
	314	Park and RajBhandary (1998) "Tatracycline-Regulated Suppression of Amber Codons in Mammalian Cells." Mol Cell Biol 18:4418-4425			
	315	Parren, Paul W.H.I. et al., "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design," Immunol. Lett. 57:105-112 (1997)			
	316	Parronchi et al., "IL-4 and IFN (☐ and ☐) Exert Opposite Regulatory Effects on the Development of Cytolytic Potential by Th1 or Th2 Human T Cell Clones," J. Immunol. 149:2977 (1992)			
	317	Paul and Seder, "Lymphocyte Responses and Cytokines," Cell 76:241 (1994)			
	318	Paulusma et al. (1996) "Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene." Science 271:1126-1128			
	319	Pelletier, Joelle N., (2001) "A Rachitt for our toolbox" Nature Biotechnology vol. 19, p. 314-315			
	320	Peng et al. (1998) "Papillomavirus Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class 1 Pathway." Virology 240:147-157			
	321	Penzes et al. (1996) "Replication and Packaging of Coronavirus Infectious Bronchitis Defective RNSa Lacking a Long Open Reading Frame." J. Virol 70:86660-8668			
	322	Phizicky, Eric M. et al., "Protein-Protein Interactions: Methods for Detection and Analysis," Microbiol Rev. 59(1):94-123 (1995)			
	323	Pletnev, A.G. et al., Chimeric Tick-Borne Encephalitis and Dengue Type 4 Viruses: Effects of Mutations on Neurovirulence in Mice," J. Virol. 67(8):4956-4963 (1993)			
	324	Polo et al. (1999) "Stable alphavirus packaging cell lines for Sidbis virus-and Semlike Forest virus-derived vectors." Proc Nat'l Acad. Sci USA> 96:4598-4603			
	325	Porcelli (1995) Adv. Immunol 59:1			
	326	Powis et al.,"Polymorphism in a second ABC transporter gene located within the class II region of the human major hisotcompatibility complex,"Proc. Nat'l. Acad. Sci. USA 89:1463-1467 (1996)			
	327	Premack et al. (1996) Nature Med. 2:1174			
	328	Pryor et al. (1998) "Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus- encoded glycoproteins." <i>J. Gen Virol.</i> 79:2631-2639			
	329	Punnonen et al. J. Exp Med. 185:993-1004			
4N	330	Punnonen et al., "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells," Proc. Nat'l. Acad. Sci. USA 90:3730 (1993)			

Examiner Signature	Shin-Lin chan	Date Considered	Jeforthing to
citation if not in	*EXAMINER: Initial if reference considered, whether or r conformance and not considered. Include copy of this form w		applicant.
	Pag	ge 16 of 21	100 mg



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE


(use as many sheets as necessary)

STATEMENT BY APPLICANT

		omplete if Known
AC	Application Number Filing Date	09/247,886
A!	Filing Date	February 10, 1999
	First Named Inventor	Juha Punnonen
	Group Art Unit	1633
	Examiner Name	S. Chen
	Attorney Docket Number	02-030210US
	Date Submitted	March 25, 2002

Su	331	Puri et al. (1998) "Complete Nucleotide Sequences Analysis of a Western Pacific Dengue-1 Virus Strain." Virus Genes 17:85-88
1	332	Racke, Michael K. et al., "Cytokine-induced Immune Deviation as a Therapy for Inflammatory Autoimmune Disease," J. Exp. Med. 180:1961-66 (1994)
	333	Rahden-staron et al. (1991) Biochem & Biophy Res. & Commun. 177(2):597-602
	334	Raj and Jones (1997) "Growth of infectious bronchitis virus vaccines in oviducts derived from oestrogen-treated chicks and embryos." <i>Vaccine</i> 15:163-168
	335	Reiser et al., "Cloning and expression of a cDNA for the T-cell-activating protein TAP," Proc. Nat'l. Acad. Sci. USA 85:2255-2259 (1988)
	336	Roden et al. (1996) "In Vitro Generation and TypeSpecific Neutralization of a Human Papillomavirus Type 16 Viron Pseudotype." <i>J. Virol.</i> 70:5875-5883
	337	Roggenkamp et al., "Passive Immunity to Infection with Yersinia spp. Mediated by Anti-Recombinant V Antigen is Dependent on Polymorphism of V Antigen," Infect. Immun. 65:446 (1997)
	338	Roncarolo et al. "Human T- and B-cell functions in SCID-hu mice," Semin. Immunol. 8: 207 (1996)
	339	Sagazio et al. (1998) "Antigenic characterization of canine parvovirus strains isolated in Italy." <i>J. Virol. Methods</i> 73:197-200
	340	Saggio et al. (1995) "CNFT Variants with increased biological potency and receptor selectivity define a functional site of receptor interaction." <i>EMBO Journal</i> 14(13):3045-3054
	341	Sakmar and Khorana, "Total synthesis and expression of a gene for the a-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin), Nucl. Acids Res. 14:6361-6372 (1988)
	342	Sanz et al. (1994) "Genetic heterogeneity of the attachment glycoprotein G among A respiratory syncytial virusus." Virus Res 33:203-217
	343	Saurmann et al. (1990) "Molecular Cloning and Characterization of a German HIV-1 Isolate." AIDS Res. Hum Retroviruses 6:813-823
	345	Sayers et al. "Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide,", Nucl. Acids Res. 16:803-814 (1988)
	346	Sayers et al., "5'-3' Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis," Nucl. Acids Res. 16:791-802 (1988)
	347	Schatz, Peter J. et al., "[10] Screening of Peptide Libraries Linked to lac Repressor," Methods Enzymol. 267:171-91 (1996)
	348	Schmaljohn, A.L. et al., "Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis," Nature 297:70 (1982)
	349	Schwarz et al. (1957) "Modification of Infevtious Bovine Rhinotrachetis (IBR) Virus in Tissue Culture and Development of a Vaccine." <i>Proc Soc Exp. Biol Med.</i> 96:453-458
	350	Schwarz et al. (1958) "Propagation and Modification of Infactious Bovine Rhinotrachetis (BR) Virus in Porcine Kidney Tissue Culture." <i>Proc Soc. Exp. Biol. Med</i> 97:680-683
	351	Scott, Jamie K. and George P. Smith, "Searching for Peptide Ligands with an Epitope Library," Science 249:386-388 (1990)
GN	352	Seliger et al., "TAP off – tumors on," Immunol. Today 18: 292-299 (1997).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through Examiner Signature



RANEM Application Number Complete if Known Substitute for form 1449A-B/PTO 09/247,886 INFORMATION DISCLOSURE Filing Date February 10, 1999 First Named Inventor Juha Punnonen STATEMENT BY APPLICANT Group Art Unit 1633 **Examiner Name** S. Chen (use as many sheets as necessary) Attorney Docket Number 02-030210US **Date Submitted** March 25, 2002

SIL	353	Sharma and Graham (1982) "Influence of Material Antibody on Efficacy of Embryo Vaccination with Cell-Associated ans Cell-Free Marek's Disease Vaccine." <i>Avian Dis.</i> 26:860-870		
1	354	Sheu et al. (1995) "Deletion or alteration of hydrophobic amino acids at the third transmembrane domains of Hepatitis B Surface antigen enhances its production in Escherichia coli." 160(2):179-184		
	355	Shouval et al. (1994) "Improved immunogenicity in Mice of a mammalian cell-derived recombinant hepatitis B Vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines." Vaccine 12(15):1453-1459		
	356	Smith, "In Vitro Mutagenesis," Ann. Rev. Genet. 19:423-462 (1985)		
	357	Sokolic et al. (1996) "A Bicistronic Retrovirus Vector Containing a Picornavirus InternationalRibosome Entry Site Allows for Correct of X-Linked CGD Selection for MDR1 Expression." <i>Blood</i> 87:42-50		
	358	Soong et al. (1998) "DNA shuffling as a tool to evolve desired retrovial phenotypes." Abstracts of papers presented at the 1998 meeting on Gene Therapy, p. 228 Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, September 23-27, 1998		
	359	Soong et al. (1998) "Directed evolution of novel retroviral tropisms by DNA shuffling." Abstract #97, Programs & Abstracts, 1st Annual Meeting of the American Society of Gene Therapy, Seattle, Washington, May 28-31, 1998		
	360	Soong et al. (1998) "Directed evolution of novel retroviral tropisms by DNA shuffling." Abstracts of papers presented at the 1998 meeting on Retroviruses, Cold Springs Harbor Laboratory, Cold Spring Harbor, New York, May 26-31, 1998		
	361	Sosnovtsev et al. (1998) "Cleavage of the Feline Calicivirus Capsid Precurrsor Is Mediated by a Virus- Encoded Proteinase." <i>J. Virol</i> 72:3051-3059		
	362	Srinivasan et al. (1987) "Molecular characterization of human immunodeiciency virus from Zaire." Gene 52:71-82		
	363	Stemmer (1991) "A 20-Minute ethidium bromide/high-salt extraction protocol for plasmid DNA." BioTechniques 10(6): 726		
	364	Stemmer (1994) <i>Nature</i> 370:389		
	365	Stemmer et al. (1991) "Expression of antibody Fv Fragments specific for a heavy metal chelate (indium-EDTA) in E. coli." <i>Journal of Cellular Biotechnology Supplement</i> 0 (15 PART G):217		
	366	Stemmer et al. (1992) "Enzymatic inverse PCR: a restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis." <i>BioTechniques</i> 13(2): 214, 216, 218-220		
		Stemmer et al. (1993) "Increased antibody expression from Escherichia coli through wobble-base library mutagenesis by enzymatic inverse PCR>" Gene 123(1): 1-7		
	368	Stemmer et al. (1993) "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR>" <i>Biotechniques</i> 14(2): 256-265		
Stern et al., "Purification to homogeneity and partial characterization of cy		Stern et al., "Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells," Proc. Nat'l. Acad. Sci. USA 87:6808 (1990)		
	370	Stohwasser et al., "Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon -γ-modulated proteasome subunits," Eur. J. Immunol. 27:1182-1187 (1997)		
4n	371	Subbarao et al. (1993) Rescue of an Influenza A Virus Wild-type PB2 Gene and a Mutant Derivative Bearing a Site-Specific Temperature-sensitive and Attenuating Mutation." J. Virol. 67:7223-7228		

Shin-Lin Chen Examiner Signature

Date Considered

Complete if Known Substitute for form 1449A-B/PTO 09/247,886 oplication Number PANEMARY INFORMATION DISCLOSURE Filing Date February 10, 1999 Juha Punnonen STATEMENT BY APPLICANT First Named Inventor Group Art Unit 1633 Examiner Name S. Chen (use as many sheets as necessary) 02-030210US Attorney Docket Number March 25, 2002 **Date Submitted**

gu	372	Sugimoto et al. (1994) "Characteristics of an attenuated vaccinia virus strain, LC16m0 and It's recombinant virus vaccines." Vaccine 12:675-681			
Ì	373	Sugimoto et al. (1995) Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human a-Galactosidase A for Gene Therapy of Febry Disease." <i>Human Gene Ther</i> 6:905-915			
374		Tahara et al., "IL-12 Gene Therapy Using Direct Injection of Tumors with Genetically Engineered Autologous Fibroblasts," Human Gene Therapy 6:1607 (1995)			
375		Tan et al., "Characterizationof Recombinant Extracellular Domain of Human Interleukin-10 Receptor," J. Biol. Chem. 270:12906 (1995)			
	376	Tang et al., "Vaccination onto bare skin," Nature 388: 729-730 (1997).			
	377	Tano et al. (1990) Proc. Nat'l Acad Sci USA 87:686-690			
	378	Tartagila et al. (1992) "NYVAC: A Highly Attenuated Strain of Vaccinia Virus." Virology 188:217-232			
	379	Tascon, Richard E. et al., "Vaccination against tuberculosis by DNA injection," Nat. Med. 2:888-92 (1996)			
	380	Taylor et al. , "The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA," Nucl. Acids Res. 13:8765-8787 (1985)			
	381	Taylor et al. , "The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA," Nucl. Acids Res. 13:8749-8764 (1985)			
	382	Thierfelder et al. "Requirement for Stat4 in interleukin-1-2-mediated responses of natural killer and T cells", Nature 382:171 (1996)			
	383	Todd (1974) "Development of Intranasal Vaccination for the Immunization of Cattle Against infectious Bovine Rhinotrachetis." <i>Can. Vet J.</i> 15:257-259			
	384	Trudel et al. , "pGATA: A Positive Selection Vector Based on the Toxicity of the Transcription Factor GATA-1 to Bacteria," Biotechniques 20:684-693 (1996).			
	385	Tytgat, G.N. ,"Review article: practical management issues for the Helicobacter pylori-infected patient at risk of gastric cancer,"Aliment. Pharmacol. Ther. 12(1):123-8 (1998)			
	386	Valle amd Falgout (1998) "Mutagenesis of the NS3 Protease of Dengue Virus Type 2." J. Virol 72:624-632			
	387	van Dinten et al. (1997) "An Infectious arterivirus cDNA clone." Proc. Nat'l Acad. Sci USA94:991-996			
	388	VanCott et al., "Antibodies with Specificity to Native gp120 and Neutralization Activity against Primary Human Immunodeficiency Virus Type 1 Isolates Elicited by Immunization with Oligomeric gp160," J. Virol. 71:4319-4330 (1997)			
	389	Vassilev et al. (1997) "Authentic and Chimeric Full-length Genomic cDNA Clones of Bovine Viral Diarrhea Virus That Yeild Infectious Transcrips." <i>J. Virol</i> 71:471-487			
	390	Velzing et al. (1999) "Induction of protective immunity against Dengue virus type 2." <i>Vaccine</i> 17:1312-1320			
	391	Villinger et al., "Comparative Sequence Analysis of Cytokine Genes from Human and Nonhuman Primates," J. Immunol. 155:3946-3954 (1995)			
4n	392	Walther et al. (1996) "Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting." <i>J. Mol. Med.</i> 74:379-392			

Examiner Signature	shin-Lin	Ohen	Date Considered	8-SPON RECEN	
citation if not in	*EXAMINER: Initial if reference consconformance and not considered. Includ		xt communication to ap	UNIA " 28-	ED,



Complete if Known Substitute for form 1449A-B/PT Application Number 09/247,886 TRANEMARY INFORMATION DISCLOSURE Filing Date February 10, 1999 Juha Punnonen STATEMENT BY APPLICANT First Named Inventor Group Art Unit 1633 **Examiner Name** S. Chen (use as many sheets as necessary) 02-030210US Attorney Docket Number **Date Submitted** March 25, 2002

32	393	Walunas et al., "CTLA-4 Can Function as a Negative Regulator of T Cell Activation," Immunity 1:405 (1994)					
1	394	Wells et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites," Gene 34:315-323 (1985)					
	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin," Phil. Trans. R. Soc. Lond. A317:415-423 (1986)						
	396	Wermeille, Joel et al., "The eradication treatments of Helicobacter pylori," Pharm. World Sci. 20:1-17 (1998)					
	397	Whelan et al. (1995) "Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones." <i>Proc. Nat'l. Acad. Sci. USA</i> 92:8388-8392					
Whitacre et al.,"Treatment of Autoimmune Disease by Oral Tolerance to Autoantigens," C Immunopathol. 80: S31-9 (1996).							
	399	Wiertz et al., "SEC61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction," Nature 384: 432 (1996).					
	400	Wiertz et al., "The Human Cytomegalovirus US11 Gene Product Dislocates MHC Class 1 Heavy Chains from the Endoplasmic Reticulum to the Cytosol," Cell 84: 769-779 (1996).					
	401	Winther et al. (1998) "Viral-Induced Rhinitis." Am J. Rhinol 12:17-20					
	402	Wisniak et al. (1974) "Hydrogen Solubility in Joboba Oil." JAOCA 51:482-485					
	403	Wloch et al., "The Influence of DNA Sequence on the Immunostimulatory Properties of Plasmid DNA Vectors," Hum. Gene Ther. 9:1439-1447 (1998)					
	404	Woody, Mary Alice et al., "Staphylococcal enterotoxin B mutants (N23K and F44S): biological effects and vaccine potential in a mouse model," Vaccine 15(2):133-139 (1997)					
	Wright et al. (1998) "Humane endpoints are an objective measure of morbidity in Venezelan encephalomyelitis virus infection of mice,' <i>Arch Virol</i> 143:1155-1162						
	406 Xiang, Z. et al., "Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines," Immunity 2:129-135 (1995) Yanagi et al. (1997) "Transcripts from a single full-length cDNA clone of hepatitis C virus are infection when directly transfected into the liver of a chimpanzee." Proc Nat'l Acad. Sci. USA 94:8738-8743						
	408	Yanagi et al. (1999) "In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone." <i>Proc. Nat'l Acad. Sci USA</i> 96:2291-2295					
	409	Yao et al. (1998) "Generation of Mutant Infectious Bursal Disease Virus That Does Not Cause Bursal Leaions." J. Virol. 72:2647-2654					
	410	Yu et al. (1995) "Functional cDNA Clones of the Human Respiratory Syncytial (RS) Virus" J. Virol 69:2412-2419					
	420	Zamvil, Scott S. and Lawrence Steinman, "The T Lymphocyte in Experimental Allergic Encephalomyelitis," Ann. Rev. Immunol. 8:579-621 (1990)					
	421	Zhong et al. (1998) "Idenification and Characterization of an RNA-Dependent RNA Polymerase Activity within the Nonstructural Protein 5B Region of Bovine Viral Diarrhea Virus," <i>J. Virol.</i> 72:9365-9369					
	422	Zhong, Weimin et al., "Therapeutic passive vaccination against chronic Lyme disease in mice," Proc.					
Su	Zoller and Smith, "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient						
Exami	ner	Shin-Lin Chen Date 8-1-1-15					
Signature		Considered Cycs 2	رم. د				
citation	if not in c	Zoller and Smith, "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and Date Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through conformance and not considered. Include copy of this form with next communication to applicant. Page 20 of 21	gh				
		~30 ₀					

MAR 2 9 2002 S

Substitute for form 1449A-B/PTO		omplete if Known
Substitute for form 1449A-b/P10	Application Number	09/247,886
INFORMATION DISCLOSURE TRADEMARY	PA-::	
INFORMATION DISCLOSURE PADEMAN	Filing Date	February 10, 1999
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen
	Group Art Unit	1633
	Examiner Name	S. Chen
(use as many sheets as necessary)	Attorney Docket Number	02-030210US
·	Date Submitted	March 25, 2002

			general procedure for the production of point mutations in any fragment of DNA," Nucl. Acids res. 10:6487-6500 (1982)			
4	u	. 424	Zoller and Smith, "Oligonucleotide-Directed Mutagenesis: A Simple Method using Two Oligonucleotide Primers and a Single-Stranded DNA Template," Methods in Enzymol. 154:329-350 (1987)			
1 1 4/3 1		425	Zoller and Smith, "Oligonucleotide-Directed Mutagenesit of DNA Fragments Cloned into M13 Vectors," Methods in Enzymol. 100:468-500 (1983)			
		426	Zou et al. (1995) "Structure-function analysis of the p35 subunit of mouse interleukin 12." <i>J. Bio. Chem.</i> 270(11):5864-5871			
		427	Zuschek et al. (1961) "Immunogenicity of 2 Infectious Bovine Rhinotracheitis Vaccines." <i>J. Am. Vet. Med. Assoc.</i> 139"236-237			
4re		428	Zygraich et al. (1974) "In Vivo and In Vitro Properties of a Temperature Sensitive Mutant of Infectious Bovine Rhinotracheitis Virus." <i>Res. Vet. Sci.</i> 16:328-335			

TECH ON THE STATE OF THE STATE

Examiner Shin—Lin Chin Signature	Date S-28-02 Considered	
----------------------------------	-------------------------	--

Application/No.: 09/247,886 Attorney Docket No.: 18097-030200US FORM PTO-1449 (Modified) Applicant: Punnonen et al. LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE Filing Date: February 10, 1999 STATEMENT (Use several sheets if necessary) Page 1 U.S. PATENT DOCUMENTS Reference Designation Filing Date Sub-class Class Name Document No. Examiner Initial (If Appropriate) Lin Short 08/17/99 5,939,250 AA 424 Stemmer, et al. 2/25/97 AB 5,605,793 Stemmer, et al. 2N 11/10/98 5,834,252 AC Stemmer, et al. LNL 11/03/98 5,830,721 AD TECH CENTER 1610/2900 Stemmer, et al. 09/22/98 SUL AE 5,811,238 Tw AF Stemmer, et al. 07/27/99 5,928,905 FOREIGN PATENT DOCUMENTS Translation Sub-class Class Country Date Document No. (Yes/No) PCT 5 June 97 WO 97/20078 AG PCT 10 Nov. 94 WO 94/25608 AH PCT 2 Oct. 97 WO 97/35957 **PCT** 8 Aug. 96 WO 96/23882 ΑJ **PCT** WO 95/26718 12 Oct. 95 ΑK SW **PCT** 25 June 98 WO98/27230 AL**PCT** SW WO 95/22625 24 Aug. 95 AM PCT WO 96/33207 24 Oct. 96 AN **PCT** WO 98/13487 2 April 98 AO OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Attridge et al., "Oral delivery of foreign antigens by attentuated Salmonella: consequences of prior exposure to the vector strain," Vaccine 15(2): 155-162 (1997). Choate and Khavari, "Sustainability of Keratinocyte Gene Transfer and Cell Survival in vivo," Human Gene Ther. ÂQ 8: 895-901 (1997). Christians, F.C. et al., "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family AR shuffling," Nature Biotechnology 17:259-264 (1999) Courvalin, et al., "Gene transfer from bacteria to mammalian cells," C.R. Acad. Sci. III 18: 1207-12 (1995). AS Crameri, A. et al., "Combinatorial Multiple Cassette Mutagenesis Creates All the Permutations of Mutant and Wild-AT Type Sequences," Biotechniques 18:194-195 (1995) Crameri, A. et al., "Construction and evolution of antibody-phage libraries by DNA shuffling," Nature Medicine AU 2:100-103 (1996) Crameri, A. et al., "DNA Shuffling of a family of genes from diverse species accelerates directed evolution," AV Nature 391:288-291 (1998) Crameri, A. et al., "Improved Green Fluorescent Protein by Molecular Evolution Using DNA Shuffling," Nature AW Biotechnology 14:315-319 (1996) Crameri, A. et al., "Molecular evolution of an arsenate detoxification pathway by DNA shuffling," Nature AX Biotechnology 15:436-438 (1997) Deng. H., et al., "Sustainable cutaneous gene delivery," Nature Biotechnol. 15: 1388-1391 (1997). ΑY Fox, M.E., et al. "Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-AZfluorocytosine by genetically engineered clostridia," Gene Ther. 3: 173-178 (1996). Fritz, J.D., "Gene Transfer into Mammalian Cells Using Histone-Condensed Plasmid DNA," Human Gene Therapy GWBA 7: 1395-1404 (1996).

JAN 1 6 2001

<i>j</i>	5 0741 1 0 20	<u>' </u>					
FORM PTO-144	9 (Modified) Attorney	ocket No.: 18097-030200U	Application No.: 09/247,886				
		onnonen et al.					
APPLICANT'S	INFORMATION DISCLOSURE Use several sheets if necessary) Filing Da	e: February 10, 1999	Group: 1632				
₹/V BB	Gates, C.M. et al., "Affinity Selective Isolation Repressor 'Headpiece Dimer" J. Mol. Biol. 2	55:1-14 (1995)					
BC	Hilgers, A.R., et al., "Caco-2 Cell Monolayers as a Model for Drug Transport Across the Intestinal Mucosa," Pharmaceutical Res. 7(9): 902-910 (1990).						
BD	Khavari and Krueger, "Cutaneous Gene Therapy," Adv. Clin. Res., Dermatologic Clinics, 15(1): 27-35 (1997).						
BE	Minshull, J. and Willem P.C. Stemmer, "Prot Biology 3:284-290 (1999)		· · · · · · · · · · · · · · · · · · ·				
BF	BF Oggoni, M.R. and Pozzi, G., "A host-vector system for heterologous gene expression in Streptococcus gordonii," Gene 169:85-90 (1996).						
BG	Patten, P.A., et al., "Applications of DNA Sh 724-733 (1997).						
вн	Pisetsky, D.S., "Immune Activation by Bacte						
BI	270:299-302 (1995)						
BJ	Stemmer, W.P.C. and N.W. Soong, "Molecular Tumor Targeting 4:1-4 (1999)						
BK	Stemmer, W.P.C. et al., "Single-step assemble oligodeoxyribonucleotides," Gene 164:49-53	(1995)					
BL	Stemmer, W.P.C., "DNA shuffling by randor evolution," <i>Proc. Natl. Acad. Sci. USA</i> 91:10	47-10751 (1994)					
BM	Stemmer, W.P.C., "Rapid evolution of a prot	en in vitro by DNA shufflin					
BN	Stemmer, W.P.C., "Searching Sequence Space	e," Biotechnology 13:549-5	53 (1995)				
BO Stemmer, W.P.C., "Sexual PCR and Assembly PCR," The Encyclopedia of Molecular Biology, VCH Publishers, New York pp. 447-457 (1996)							
BP Stemmer, W.P.C., "The Evolution of Molecular Computation," Science 270:1510 (1995)							
SWBQ.	Zhang, J. et al., "Directed evolution of a fuco Natl. Acad. Sci. USA 94:4504-4509 (1997)	sidase from a galactosidase	by DNA shuffling and screening," Proc.				
	,		0				
EXAMINER	Shin-Lin han DATE	CONSIDERED Y	29-02				

JAN 1 6 2001

USPTO-1449 (Modified)			Docket 018097-0302000 RADEMP Application No.: 09/247,886				
LIST OF PATE	NTS AND PUBLI	CATIONS FOR	Applicant: Punnonen et a				
APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Filing Date: February 10, 19999		Group: 1632		
Reference Desig		Ţ	J.S. PATENT DOCUME	NTS		Page 1	
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)	
GN BR	5,338,665	08/16/94	Schatz et al.				
					 	RECEIVED	
						RECEIVED JAN 19 2001	
						TEH COTTER 160	
		FO	REIGN PATENT DOCU	MENTS			
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)	
			luding Author, Title, Da	te Pertinent Page	Etc.)		
	0	THEK AKI (Inc	inding Author, Title, Da	10, 1 01 1110111 1 1601	-,		
				<i>D</i> -	18 2		
EXAMINER	Shin-L	in Chen	DATE CONSIDERE	D &	21-02		